Compare GLU & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | ELTX |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5M | 158.5M |
| IPO Year | N/A | N/A |
| Metric | GLU | ELTX |
|---|---|---|
| Price | $18.53 | $8.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 12.4K | ★ 111.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $4.60 |
| 52 Week High | $15.40 | $12.62 |
| Indicator | GLU | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 44.84 |
| Support Level | $18.32 | $7.90 |
| Resistance Level | $18.61 | $9.00 |
| Average True Range (ATR) | 0.20 | 0.61 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 54.59 | 38.69 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.